Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Single-center study outlines stroke risk, DOAC type in nonvalvular AFib patients

Key clinical point: Rivaroxaban was associated with a disproportionate number of breakthrough strokes among patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants at one stroke unit in Australia.

Major finding: Despite accounting for about 51% of Australian DOAC prescriptions, rivaroxaban represented nearly 73% of breakthrough strokes among the patients who had strokes while receiving treatment (P = .001).

Study details: Retrospective study of 56 patients with nonvalvular atrial fibrillation reporting to a tertiary care stroke unit in Australia.

Disclosures: The authors reported no financial disclosures.

Citation:

Chan F et al. AAN 019. Poster P1.3-001.